Bain Capital Life Sciences Fund Sells $56.1M in Heartflow Stock
Summary
Bain Capital Life Sciences Fund, a 10% owner, reported an open market sale of $56.1 million worth of Heartflow common stock.
Key Events
-
Significant Stock Sale
Bain Capital Life Sciences Fund III, L.P., a 10% owner, disposed of 2,000,000 shares of Heartflow common stock for a total value of $56.1 million at a price of $28.05 per share.
-
Post-Transaction Holdings
Following this transaction, Bain Capital Life Sciences Fund III, L.P. and its affiliated entities indirectly hold 10,448,158 shares.
-
Follows Prior Intent to Sell
This open market sale on February 4, 2026, follows a Form 144 filing on February 5, 2026, which indicated an intent to sell shares.
Analysis
This significant open market sale by Bain Capital Life Sciences Fund, a major institutional investor and 10% owner, could signal a rebalancing of their portfolio or a shift in their investment outlook for Heartflow. While institutional investors often sell for liquidity or portfolio management, the substantial value of this transaction warrants attention from the market. Investors should monitor for any further sales or related announcements from Bain Capital.
At the time of this filing, HTFL was trading at $28.03 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $25.38 to $41.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.